On August 10, 2020 JW Therapeutics, a clinical-stage biopharmaceutical company focused on developing, manufacturing and commercializing cell therapies for patients in China, reported entering into a development and commercialization agreement with Lyell Immunopharma to advance adoptive T cell therapy for the treatment of hepatocellular carcinoma in China and ASEAN countries (Press release, JW Therapeutics, AUG 10, 2020, View Source [SID1234638724]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The collaboration combines Lyell’s proprietary T cell anti-exhaustion technology, which is intended to preserve or maintain T cell function, with JW Therapeutics’ recent acquisition of Syracuse and its ARTEMIS technology platform. The companies’ complementary capabilities in developing and manufacturing cell-based products may help advance new treatment options for patients in China and other parts of Asia.

JW Therapeutics and Lyell Immunopharma intend to seek additional opportunities for collaboration in research, development, and commercialization of products in China.

Terms of the collaboration were not disclosed.